Onco-Innovations: Safeguarding AI-Driven Precision Medicine with SynoGraph

Onco-Innovations Limited (CSE: ONCO) (Frankfurt: W1H, WKN: A3EKSZ), a Canadian-based company dedicated to cancer research and treatment, has taken a significant step towards protecting its innovative approach to AI-driven precision medicine. On January 28, 2025, the company's wholly-owned subsidiary, Inka Health, filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its next-generation AI platform, SynoGraph. This move marks an important milestone in safeguarding Onco's proprietary AI technology and strengthening its position in the healthcare technology sector.

SynoGraph, a transformative AI-powered tool, is designed to accelerate precision oncology breakthroughs while de-risking drug development processes. The platform leverages AI-powered causal inference to identify cancer patients likely to respond to specific treatments, integrating diverse multimodal medical data, including genomics, transcriptomics, and proteomics. By uncovering previously hidden insights, SynoGraph aims to optimize treatment decisions and clinical trial design, ultimately enhancing patient outcomes and reducing development costs.

The provisional patent application for SynoGraph is a crucial step in protecting Onco's innovative approach to AI-driven precision medicine. By safeguarding this proprietary technology, the company ensures that SynoGraph remains a valuable asset in AI-driven drug development. This move not only strengthens Onco's position in the healthcare technology sector but also opens doors for strategic collaborations and commercialization opportunities.

Inka Health, the developer of SynoGraph, has already established partnerships with industry leaders such as AstraZeneca Canada and global data holders like Quantify Research. These collaborations demonstrate Inka Health's commitment to fostering collaboration with industry leaders and its ability to deliver transformative solutions in precision medicine. By acquiring Inka Health, Onco can tap into these established contracts and further strengthen its position in the growing global AI in healthcare market.

The global artificial intelligence (AI) in healthcare market is projected to soar to USD 613.81 billion by 2034, with a remarkable compound annual growth rate (CAGR) of 36.83%. North America continues to dominate the market, generating over 45% of total revenue in 2023, driven by its advanced digital infrastructure and strong healthcare, IT, and telecommunications sectors. By leveraging SynoGraph's innovative approach to precision medicine, Onco can capitalize on this high-growth market and position itself for long-term success.



In conclusion, Onco-Innovations' filing of a provisional patent application for SynoGraph is a strategic move that safeguards the company's proprietary AI technology and strengthens its position in the healthcare technology sector. By leveraging SynoGraph's innovative approach to precision medicine, Onco can attract strategic collaborations, commercialization opportunities, and capitalize on the growing global AI in healthcare market. As the company continues to push the boundaries of AI-driven precision medicine, investors can expect Onco to maintain a competitive edge in the market and deliver value to shareholders.